Business & Finance
Business and Finance
Business and Finance
Wed, June 3, 2009Tue, June 2, 2009Mon, June 1, 2009Sat, May 30, 2009Fri, May 29, 2009Thu, May 28, 2009Wed, May 27, 2009Tue, May 26, 2009Mon, May 25, 2009Sun, May 24, 2009Fri, May 22, 2009Thu, May 21, 2009Wed, May 20, 2009Tue, May 19, 2009Mon, May 18, 2009Fri, May 15, 2009Thu, May 14, 2009Wed, May 13, 2009Tue, May 12, 2009Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. Announces Presentation at 2nd Annual HOPE Conference for Parkinson's
Published in Business and Finance on Friday, May 22nd 2009 at 5:38 GMT, Last Modified on 2009-11-02 11:56:30 by Market Wire
CALGARY, ALBERTA--(Marketwire - May 22, 2009) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) (the "Company" or "SCT") is pleased to announce that Dr. Allen Davidoff, VP Product Development, will be the featured speaker this evening at the 2nd Annual HOPE Conference for Parkinson's. The Conference is hosted by the Parkinson's Society of Southern Alberta and will take place at the Carriage House Inn, May 22-23 in Calgary, Alberta.
Dr. Davidoff will be discussing the possibility of drug-based therapies to regenerate brain tissue and improve outcomes for individuals who have experienced losses due to central nervous system diseases, such as Parkinson's disease.
Dr. Allen Davidoff commented that "even though Parkinson's disease is not one of our three focus areas of stroke, traumatic brain injury and multiple sclerosis, it still represents an important application for our technology and intellectual property, and is one that we would like to develop with a collaborative partner."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair neurological function lost due to disease or injury. SCT's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
